Phase 1Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
Sponsored by Sumitomo Pharma America, Inc.
About this study
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Enrolling at this location
SCRI Oncology Partners
Nashville, Tennessee
I'm interestedThis study also enrolls at 9 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.